SHANGHAI, Sept. 20, 2020 /PRNewswire/ -- Shanghai SIMR
Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or
"Company") announced that, the clinical trial in patients with
peripheral neuropathic pain has been initiated for the candidate
drug SR419, and the first patient has been successfully dosed.
The current clinical trial is the first study for SR419 in the
patient population, purposing to explore the efficacy, safety,
tolerability and pharmacokinetics of SR419 in patients with
neuropathic pain.
Dr. Kai Wu, Co-CEO and Head of
Clinical Development of SIMR, said: "Previous clinical results
demonstrated that SR419 was safe and tolerable with good
pharmacokinetic characteristics, which ensured the success to
initiate the current trial in the patient population."
Dr. Shuai Li, founder and
chairman of SIMR, said: "The socio-economic burden caused by
chronic pain is huge. For example, the overdose of opioids causes
more than 100,000 deaths worldwide every year. Based on the
available preclinical and clinical data, SR419 has the potential to
replace opioids, so we very much look forward to the outcome from
this trial for SR419!
About SR419
SR419 is a candidate drug of novel mechanism for the treatment of
peripheral neuropathic pain, discovered and developed by SIMR. It
has successfully completed the first-in-human phase I clinical
trial. SR419 has the potential of strong analgesic efficacy and no
CNS side effects.
About peripheral neuropathic pain
Peripheral neuropathic pain is the pain caused by damage or
pathological changes of peripheral nerves, including post-herpetic
neuralgia, diabetic peripheral neuropathy, chemotherapy-induced
peripheral neuropathy, and postoperative peripheral neuropathy.
Epidemiological data show that the incidence of neuropathic pain in
the general population is about 8%. Diabetic peripheral neuropathy
affects about 50% of diabetic patients, and chemotherapy-induced
peripheral neuropathy affects nearly 60% of cancer patients after
chemotherapy. As the standard treatment for neuropathic pain, the
annual global sales of pregabalin (Lyrica) has reached about
$3 to $5
billion in the past 5 years, but its efficacy is not ideal,
with nearly 50% of patients not experiencing effective pain relief
after treatment. Therefore, there are significant unmet medical
needs for this disease.
About SIMR
SIMR is an innovation-oriented biopharmaceutical company dedicated
to the discovery and development of new drugs for pain and other
nervous system diseases.
For more information on SIMR, please visit
http://www.simrbio.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/key-milestone-the-first-patient-successfully-dosed-with-the-candidate-drug-sr419-for-peripheral-neuropathic-pain-301134418.html
SOURCE Shanghai SIMR Biotech Co.,Ltd